Research and insights on market trends and best practices from BioCentury and our selected sponsors and collaborators.
BioCentury's spotlight on "Real-World Evidence" highlights BioCentury's recent coverage and analysis into the opportunities for Western pharmaceutical companies to accelerate drug development processes in China using the Real World Evidence (RWE) approval pathway.
BioCentury's popular "Korea Spotlight" series heads to the China Summit where a panel of Korea biotech CEOs discuss opportunities for cross-border partnerships and drug development.
To stage its Next Act, Europe will need to transform its powerhouse of scientific research into a pipeline of new medicines with global impact. How — and where — will Europe create more leading biotechs to make this happen? To answer that question, Insights Partner McKinsey & Co. returns with its new exclusive report for Bio€quity Europe. This second annual report builds on McKinsey’s leading analysis of Europe’s “Innovation Hot Spots,” addressing key questions about the trajectory of these evolving centers of excellence and how they measure up to key metrics for growth and success.
Sponsor Edition - Eight parameters to optimize your technology strategy
Disruptions to clinical trials that prevent or limit site access to patients, monitors, and CRAs are propelling long-lasting changes in the research industry, supported by the adoption of trial virtualization technologies. Download this eBook to learn eight parameters that are driving the successful response and approach to decentralized trials to guide sponsors in optimizing their technology strategy.
The exclusive Broadening the Bridge to Innovation by McKinsey & Company was commissioned for the 7th BioCentury-BayHelix China Healthcare Summit (Nov. 9-13, 2020, Digital Event).
The exclusive China MedTech – Path to a Global Leading Market by McKinsey & Company was commissioned for the 7th BioCentury-BayHelix China Healthcare Summit (Nov. 9-13, 2020, Digital Event).
In this white paper, discover how CTOs are evaluating the latest developments, identifying new trends, approaching new technology deployment, and looking into the adoption of unified platform solutions.
In a time of unprecedented volatility in the public equity capital markets, institutional funds providing Royalty and Revenue Interest Financing (“RIF”) have demonstrated their confidence in the long-term revenue potential of important biopharma and medical device products by providing record levels of capital funding on attractive terms.
Biotechnology and pharma companies alike are under pressure to develop new drugs, diagnostics, and medical devices faster and faster. But due to an inherent resource gap, small and medium-sized (SME) biotech firms are at a disadvantage right from the start. This white paper shares four tactics SMES should consider as they seek new ways to minimize R&D costs, speed development, and improve research outcomes.
BioCentury's coverage of COVID-19 diagnostics highlights how the crisis is accelerating development of new technologies, and how researchers and authorities are seeking to resolve the tension between the dueling needs for urgency and accuracy.
What are the latest trends shaping the biopharma industry in China? Based on interviews with biopharma C-suite from China and the West, the exclusive Running on the China Bridge to Innovation by McKinsey & Company was commissioned for the 6th BioCentury-BayHelix China Healthcare Summit (Nov. 18-20, 2019, Shanghai).